drugset / Trial / NCT00413920

Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients

NCT00413920

Phase 3 Completed 222 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will investigate the efficacy and safety of a steroid avoidance regimen in comparison with steroid treatment in combination with an initially higher dose of enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine microemulsion in de novo renal transplant recipients. Patients will be randomly allocated to receive either EC-MPS or steroids in combination with EC-MPS. Patients of both treatment groups will receive monoclonal antibody induction therapy and a perioperative bolus of steroids and cyclosporine.

Timeline

Start
2007-04
Primary completion
2009-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisone Other / unclassified Oral
Subject mycophenolic acid Small molecule 720 mg Oral

Indications

No indication recorded.